Payment overview · 2025
General Payments
$2,152.88
56 reported records · 11 companies
Healthcare provider profile · identity verified
Frantony Mercado Cabrera, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · MAYAGUEZ, PR · NPI 1255774832
Verified facts
What the public records show
CMS Open Payments records show Frantony Mercado Cabrera, MD received $2,152.88 in general payments during 2025 across 56 reported records.
Abbott Laboratories accounted for 63.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Eliquis by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Xarelto by this doctor in 2024.
PBG PUERTO RICO LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 738 records involving 435 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $1,362.49 | 63.3% | 24 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$220.42 | 10.2% | 6 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $136.94 | 6.4% | 10 | 2025 |
| PBG PUERTO RICO LLC | Unresolved — no canonical attribution shown | $104.51 | 4.8% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $74.19 | 3.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $61.05 | 2.8% | 3 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $54.97 | 2.5% | 2 | 2025 |
| Bayer Puerto Rico Inc. | Unresolved — no canonical attribution shown | $45.32 | 2.1% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $42.79 | 2.0% | 1 | 2025 |
| Terumo Medical Corporation | Unresolved — no canonical attribution shown | $27.00 | 1.2% | 1 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $23.20 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,202.80 | 51 |
| Travel and Lodging | $950.08 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ULTREON Normalized: ultreon |
Device | Abbott Laboratories | $757.18 | 5 | 2025 |
Source payment records
|
|||||
| DRAGONFLY OPSTAR Normalized: dragonfly opstar |
Device | Abbott Laboratories | $383.63 | 8 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $98.02 | 1 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $85.04 | 1 | 2025 |
Source payment records
|
|||||
| LUX-Dx Insertable Cardiac Monitor Normalized: lux dx insertable cardiac monitor |
Device | Boston Scientific Corporation | $75.00 | 1 | 2025 |
Source payment records
|
|||||
| Repatha Normalized: repatha |
Biological | Amgen Inc. | $74.19 | 1 | 2025 |
Source payment records
|
|||||
| MICRA Normalized: micra |
Device | Medtronic, Inc. | $63.63 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $61.05 | 3 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PBG PUERTO RICO LLC | $60.00 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Puerto Rico Inc. | $45.32 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PBG PUERTO RICO LLC | $44.51 | 2 | 2025 |
Source payment records
|
|||||
| WINREVAIR Normalized: winrevair |
Biological | Merck Sharp & Dohme LLC | $42.79 | 1 | 2025 |
Source payment records
|
|||||
| COBALT DR MRI SURESCAN Normalized: cobalt dr mri surescan |
Device | Medtronic, Inc. | $38.00 | 2 | 2025 |
Source payment records
|
|||||
| GALLANT Normalized: gallant |
Device | Abbott Laboratories | $37.91 | 2 | 2025 |
Source payment records
|
|||||
| OPTIS Normalized: optis |
Device | Abbott Laboratories | $29.62 | 2 | 2025 |
Source payment records
|
|||||
| DIAMONDBACK CORONARY Normalized: diamondback coronary |
Device | Abbott Laboratories | $27.48 | 4 | 2025 |
Source payment records
|
|||||
| HEARTRAIL Normalized: heartrail |
Device | Terumo Medical Corporation | $27.00 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PBG PUERTO RICO LLC | $25.65 | 1 | 2025 |
Source payment records
|
|||||
| JOT DX Normalized: jot dx |
Device | Abbott Laboratories | $24.75 | 1 | 2025 |
Source payment records
|
|||||
| KENGREAL Normalized: kengreal |
Drug | Chiesi USA, Inc. | $23.20 | 1 | 2025 |
Source payment records
|
|||||
| Wolverine Coronary Cutting Balloon Normalized: wolverine coronary cutting balloon |
Device | Boston Scientific Corporation | $21.30 | 2 | 2025 |
Source payment records
|
|||||
| PULSESELECT Normalized: pulseselect |
Device | Medtronic, Inc. | $20.77 | 1 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $18.45 | 1 | 2025 |
Source payment records
|
|||||
| QUARTET Normalized: quartet |
Device | Abbott Laboratories | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $7.08 | 2 | 2025 |
Source payment records
|
|||||
| FFR Link Bluetooth Communication Module Normalized: ffr link bluetooth communication module |
Device | Boston Scientific Corporation | $4.58 | 1 | 2025 |
Source payment records
|
|||||
| General - Balloon Catheters Normalized: general balloon catheters |
Device | Boston Scientific Corporation | $4.16 | 1 | 2025 |
Source payment records
|
|||||
| General - Stents Normalized: general stents |
Device | Boston Scientific Corporation | $3.88 | 1 | 2025 |
Source payment records
|
|||||
| General - Atherectomy Normalized: general atherectomy |
Device | Boston Scientific Corporation | $2.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 41 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
41 | 13 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
49 | 20 |
| PBG PUERTO RICO LLC Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 738 supporting records · 435 recipient NPIs · example record 1228798592 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
41 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 291 | 101 |
| Metoprolol Succinate | Metoprolol Succinate | 232 | 83 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 231 | 85 |
| Clopidogrel | Clopidogrel Bisulfate | 216 | 75 |
| Chlorthalidone | Chlorthalidone | 181 | 67 |
| Amlodipine Besylate | Amlodipine Besylate | 160 | 64 |
| Ezetimibe | Ezetimibe | 134 | 45 |
| Carvedilol | Carvedilol | 128 | 44 |
| Farxiga | Dapagliflozin Propanediol | 119 | 38 |
| Losartan Potassium | Losartan Potassium | 115 | 43 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 112 | 38 |
| Candesartan Cilexetil | Candesartan Cilexetil | 110 | 33 |
| Entresto | Sacubitril/Valsartan | 98 | 28 |
| Furosemide | Furosemide | 82 | 34 |
| Lisinopril | Lisinopril | 77 | 32 |
| Xarelto | Rivaroxaban | 49 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 46 | 19 |
| Eliquis | Apixaban | 41 | 13 |
| Jardiance | Empagliflozin | 38 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 37 | suppressed |
| Famotidine | Famotidine | 37 | 14 |
| Nifedipine Er | Nifedipine | 37 | 17 |
| Irbesartan | Irbesartan | 36 | 13 |
| Brilinta | Ticagrelor | 35 | 12 |
| Spironolactone | Spironolactone | 35 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 32 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 28 | suppressed |
| Bumetanide | Bumetanide | 27 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 26 | suppressed |
| Metformin Hcl | Metformin Hcl | 25 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Simvastatin | Simvastatin | 25 | suppressed |
| Repatha Sureclick | Evolocumab | 22 | suppressed |
| Ranolazine Er | Ranolazine | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 18 | suppressed |
| Omeprazole | Omeprazole | 16 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 12 | suppressed |
| Gabapentin | Gabapentin | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,152.88 · 56 records | Abbott Laboratories | AVEIR, AVVIGO Guidance System, CAMZYOS, COBALT DR MRI SURESCAN, COREVALVE EVOLUT R, DIAMONDBACK CORONARY, DRAGONFLY OPSTAR, ELIQUIS, FFR Link Bluetooth Communication Module, GALLANT, General - Atherectomy, General - Balloon Catheters, General - Stents, General - Therapies, HEARTRAIL, JOT DX, KENGREAL, Kerendia, LUX-Dx Insertable Cardiac Monitor, MICRA, NURTEC ODT, OPTIS, PULSESELECT, QUARTET, Repatha, ULTREON, VYNDAQEL, WINREVAIR, Wolverine Coronary Cutting Balloon | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error